Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06229847
Other study ID # Mindful Eating-DM
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 1, 2019
Est. completion date December 30, 2019

Study information

Verified date January 2024
Source Goztepe Prof Dr Suleyman Yalcin City Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to learn about the association of the level of mindful eating with the current glycemic control in patients with type 2 diabetes. The researchers will compare different glycemic control levels with the participants mindfulness while eating. And secondly, the researchers will compare the levels of eating awareness of those with and without obesity.


Description:

In type 2 diabetes, life style adaptations, mainly healthy eating, weight loss or control and exercise constitutes the foundation of type 2 diabetes management. In addition to regulating blood sugar levels, lifestyle modifications play a significant role in controlling risk factors such as hypertension and hyperlipidemia, delaying/preventing complications from developing, and even promoting diabetes regression. It is essential not only to focus on healthy food choices in dietary therapy but also to ensure patients achieve weight loss. Another crucial point is maintaining the continuity of these lifestyle changes. It is reported that it is quite challenging for patients to make lifestyle changes, adapt to the offered treatments, and furthermore, sustain this as a way of life. Adherence to these dietary changes is crucial for long-term success in managing diabetes and achieving weight loss goals. In a cross-sectional study conducted by Fanning and colleagues with 148 type 2 diabetic patients, it was found that "conscious eating" is associated with better diet adherence. In a review by Dunn et al., the available data strongly support the necessity of "conscious eating" as part of weight management programs. An American Heart Association statement highlights strong evidence that irregular eating patterns can make it difficult to maintain a healthy cardiometabolic profile, and emphasizes that conscious attention to mealtime and frequency can contribute to a healthier lifestyle and better management of cardiometabolic risk factors. In this study, the aim was to investigate the degree of eating mindfulness of patients with type 2 diabetes, and compare it between patients who had good glycemic control and patients with poorly controlled glycemic.


Recruitment information / eligibility

Status Completed
Enrollment 448
Est. completion date December 30, 2019
Est. primary completion date November 30, 2019
Accepts healthy volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - given consent to the study - having applied to Diabetes Outpatient Clinic for diabetes management - having diagnosed with type 2 diabetes for at least 6 months - having the mental competence to answer the questions in the questionnaire Exclusion Criteria: - Inconclusive diagnosis of type 2 diabetes - having not received or not using any treatment for diabetes

Study Design


Locations

Country Name City State
Turkey Istanbul Medeniyet University Goztepe Research and TRaining Hospital Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Goztepe Prof Dr Suleyman Yalcin City Hospital

Country where clinical trial is conducted

Turkey, 

References & Publications (4)

Dunn C, Haubenreiser M, Johnson M, Nordby K, Aggarwal S, Myer S, Thomas C. Mindfulness Approaches and Weight Loss, Weight Maintenance, and Weight Regain. Curr Obes Rep. 2018 Mar;7(1):37-49. doi: 10.1007/s13679-018-0299-6. — View Citation

Fanning J, Osborn CY, Lagotte AE, Mayberry LS. Relationships between dispositional mindfulness, health behaviors, and hemoglobin A1c among adults with type 2 diabetes. J Behav Med. 2018 Dec;41(6):798-805. doi: 10.1007/s10865-018-9938-3. Epub 2018 May 25. — View Citation

Mason AE, Saslow L, Moran PJ, Kim S, Wali PK, Abousleiman H, Hartman A, Richler R, Schleicher S, Hartogensis W, Epel ES, Hecht F. Examining the Effects of Mindful Eating Training on Adherence to a Carbohydrate-Restricted Diet in Patients With Type 2 Diabetes (the DELISH Study): Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2019 Feb 20;8(2):e11002. doi: 10.2196/11002. Erratum In: JMIR Res Protoc. 2020 Jan 13;9(1):e17226. — View Citation

St-Onge MP, Ard J, Baskin ML, Chiuve SE, Johnson HM, Kris-Etherton P, Varady K; American Heart Association Obesity Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Meal Timing and Frequency: Implications for Cardiovascular Disease Prevention: A Scientific Statement From the American Heart Association. Circulation. 2017 Feb 28;135(9):e96-e121. doi: 10.1161/CIR.0000000000000476. Epub 2017 Jan 30. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary mindful eating, its subgroups and diabetes control in patients with type 2 diabetes To investigate the relationship between mindful eating and its subgroups with glycemic control, as evaluated by HbA1c, in individuals diagnosed with type 2 diabetes for at least 6 months. baseline
Secondary mindful eating, its subgroups and the presence of obesity in patients with type 2 diabetes To investigate the relationship between mindful eating and its subgroups with obesity, as evaluated by body mass index, in individuals diagnosed with type 2 diabetes for at least 6 months. baseline
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A